Men's Journal reports GLP-1 users are buying more add-on supplements, while doctors question the claims behind them and the quality of what's sold.
Recap by typeshit. Full story at Men's Journal on MSN.
Lilly's retatrutide is still in development with no FDA approval, yet CBS investigators found vials labeled 'reta' easy to buy across the internet and in shops.
A systematic review cited by Dr. Axe found human safety data on BPC-157 comes from just 30 people, a thin base for a widely used peptide.
A short post from the endocrinologist pushing back on headlines tying the eye condition to GLP-1 drugs, urging people to look at the data.
A brief post notes growing concern over reports of serious eye problems in people taking Ozempic and similar drugs, while research into the link continues.
Polish Radio reports results for amycretin, another obesity candidate in Novo's pipeline. Details are at the source.
GoodRx says approved peptides went through safety and effectiveness testing, while wellness peptides sold without approval lack that evidence and carry risks.
Loading…